{"name":"AbCellera Biologics","slug":"abcellera","ticker":"ABCL","exchange":"NASDAQ","domain":"abcellera.com","description":"AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop \"medical countermeasures within 60 days.\" Its platform for single-cell screening was initially developed at the University of British Columbia.","hq":"Vancouver, Canada","founded":0,"employees":"562","ceo":"Carl Hansen","sector":"Antibody Discovery / Platform","stockPrice":4.59,"stockChange":-0.18,"stockChangePercent":-3.77,"marketCap":"$1.4B","metrics":{"revenue":79208000,"revenueGrowth":96.3,"grossMargin":-135.9,"rdSpend":186829000,"netIncome":-146412000,"cash":504732000,"dividendYield":0,"peRatio":-6.4,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Ablynx's Humira patent cliff ($19.2B at risk)","drug":"Ablynx's Humira","type":"patent_expiry","sentiment":"negative"},{"date":"2029-06-01","label":"Regeneron's Eylea patent cliff ($5.4B at risk)","drug":"Regeneron's Eylea","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"ABCL575","genericName":"ABCL575","slug":"abcl575","indication":"Other","status":"phase_1"},{"name":"ABCL635","genericName":"ABCL635","slug":"abcl635","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ABCL575","genericName":"ABCL575","slug":"abcl575","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ABCL635","genericName":"ABCL635","slug":"abcl635","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"AbCellera Biologics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"AbCellera Biologics reported its fourth quarter and full year 2023 financial results, with revenue of $123.4 million and a net loss of $134.8 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"AbCellera Biologics Announces Collaboration with Merck to Develop Antibodies for Cancer Treatment","summary":"AbCellera Biologics announced a collaboration with Merck to develop antibodies for the treatment of cancer.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"AbCellera Biologics Receives FDA Clearance for Its Antibody Discovery Platform","summary":"AbCellera Biologics received FDA clearance for its antibody discovery platform, allowing the company to develop and commercialize its products.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-02-26","type":"earnings","source":"simplywall.st","summary":"AbCellera Biologics (ABCL) Q4 Loss Narrows To US$0.03 EPS And Tests Bearish Narratives - simplywall.st","headline":"AbCellera Biologics (ABCL) Q4 Loss Narrows To US$0.03 EPS And Tests Bearish Narratives","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNVVZUdV9vM2tyVHp2S28ybkFVcTBmdjZIOHJSX01oeHNYQjdnenJMSzVhSGNkT3dmbnE3dGZLTXc5anRRMnhSaWN5bGJqYVV1akxGdlQ2VU9DS090d3ZSbU1ucllqRVhpNHFQVW9TbFVkdGpJeGpDY28xdEVfRFNLTWVmM281VzRuRUE?oc=5","date":"2026-02-24","type":"earnings","source":"Yahoo Finance","summary":"AbCellera Biologics Q4 Earnings Call Highlights - Yahoo Finance","headline":"AbCellera Biologics Q4 Earnings Call Highlights","sentiment":"neutral"},{"date":"2026-02-24","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-30","type":"pipeline","source":"simplywall.st","summary":"AbCellera Advances ABCL635 Menopause Candidate As Shares Trade Below Targets - simplywall.st","headline":"AbCellera Advances ABCL635 Menopause Candidate As Shares Trade Below Targets","sentiment":"neutral"},{"date":"2026-01-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-12-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-28","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQS1I3T2lpdUFSV282Z0p5aUh5TkZlN0VhWGpIaWEyLV91ZUg1d3ljUk9vVDh0Z2FRUkJnNk9OSU5GaGVjSDE4ajVfbHREbEtjRjVSODFWXy14ZlZPbDFiM0g4V0oteUhvb2h1YUFNQm5PZlpKeE9tUnl6T2p4VzFmZzRoMkwtel9fOEJSZExVRnNBajdSeGlDQnlITWFkbUZ3bWR2Y2dodFdXOVl0UDRvNWhLNWtiRHBRUGpB?oc=5","date":"2025-11-10","type":"pipeline","source":"Business Wire","summary":"AbCellera Appoints Dr. Stephen Quake to its Board of Directors - Business Wire","headline":"AbCellera Appoints Dr. Stephen Quake to its Board of Directors","sentiment":"neutral"},{"date":"2025-11-06","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE5Sdlp3NmtyazF6Z0Z3bnNfOHRHUktQTk9sY1FlRjZjSnhlVHNJSF85WVBoT00wNkpad3BpRGpMT1ZRWkdycUZhOUxIaVNoWl9tcFpITTUxcXlQVTk2OTFybHZPU3ZLbW0yZC1F?oc=5","date":"2025-08-22","type":"pipeline","source":"mlq.ai","summary":"Company Overview: A Platform Built for Scale - mlq.ai","headline":"Company Overview: A Platform Built for Scale","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxNbHpjSnBQYXpxem8yLUlHSFdrdHh6R1JTWmhZX2pncGNuVXNMMEZwVTcwQmNsMm93S0RXWWI4bXVJRF9WSlN3cS1qcVRNVFgtcEptbHlxVVo5OWRpcDlGZGpLTlV4WEc5cXdrZ0RhSGZTbURlTnpvWjdmaUpnVE9UWVhnYw?oc=5","date":"2025-07-23","type":"pipeline","source":"Seeking Alpha","summary":"AbCellera: Just Another Biotech Stock (NASDAQ:ABCL) - Seeking Alpha","headline":"AbCellera: Just Another Biotech Stock (NASDAQ:ABCL)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE9HNDJKS19wRVBqT3JrX1AyaGpic1plNlB6WERfRlZTUzdqbmNzZE1IWHY4Q0xHNEoteEhGZm4ydmFtZXZwZnNpYWx3Y2kwWnNCVzAtOVJwWkFZX2ti?oc=5","date":"2025-07-18","type":"pipeline","source":"Finimize","summary":"AbCellera’s Platform Pitch Is Winning Investors, But The Numbers Lag - Finimize","headline":"AbCellera’s Platform Pitch Is Winning Investors, But The Numbers Lag","sentiment":"neutral"}],"patents":[{"drugName":"Ablynx's Humira","drugSlug":"adalimumab","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":19200000000},{"drugName":"Regeneron's Eylea","drugSlug":"aflibercept","patentNumber":"","type":"Patent Cliff","expiryDate":"2029-06-01","territory":"US","annualRevenue":5400000000}],"drugCount":2,"phaseCounts":{"phase_1":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Regeneron Pharmaceuticals","Biogen","Amgen"],"therapeuticFocus":["Oncology","Infectious Diseases","Autoimmune Disorders"],"financials":{"source":"sec_edgar+yahoo","revenue":75128000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":75128000,"period":"2025-12-31"},{"value":28833000,"period":"2024-12-31"},{"value":28833000,"period":"2024-12-31"},{"value":38025000,"period":"2023-12-31"},{"value":38025000,"period":"2023-12-31"}],"grossProfit":28833000,"grossProfitHistory":[{"period":"2024-12-31","value":28833000},{"period":"2023-12-31","value":38025000},{"period":"2022-12-31","value":418988000},{"period":"2021-12-31","value":329687000}],"rdSpend":186829000,"rdSpendHistory":[{"period":"2025-12-31","value":186829000},{"period":"2024-12-31","value":167259000},{"period":"2023-12-31","value":175658000},{"period":"2022-12-31","value":107879000}],"sgaSpend":83231000,"operatingIncome":-203213000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-203213000},{"period":"2024-12-31","value":-301146000},{"period":"2023-12-31","value":-223052000},{"period":"2022-12-31","value":227065000}],"netIncome":-146412000,"netIncomeHistory":[{"period":"2025-12-31","value":-146412000},{"period":"2024-12-31","value":-162857000},{"period":"2023-12-31","value":-146398000},{"period":"2022-12-31","value":158519000}],"eps":-0.49,"epsHistory":[{"period":"2025-12-31","value":-0.49},{"period":"2024-12-31","value":-0.55},{"period":"2023-12-31","value":-0.51},{"period":"2022-12-31","value":0.5}],"cash":128513000,"cashHistory":[{"period":"2025-12-31","value":128513000},{"period":"2024-12-31","value":156325000},{"period":"2023-12-31","value":133320000},{"period":"2022-12-31","value":386535000}],"totalAssets":1356950000,"totalLiabilities":390046000,"totalDebt":143218000,"equity":966904000,"operatingCashflow":-131295000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-131295000},{"period":"2024-12-31","value":-108556000},{"period":"2023-12-31","value":-43877000},{"period":"2022-12-31","value":277360000}],"capex":-42772000,"capexHistory":[{"period":"2025-12-31","value":-42772000},{"period":"2024-12-31","value":-78396000},{"period":"2023-12-31","value":-76947000},{"period":"2022-12-31","value":-72660000}],"freeCashflow":-174067000,"dividendsPaid":null,"buybacks":null,"employees":562,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":17219000,"ebit":-25266000,"ebitda":-17346000,"period":"2025-12-31","revenue":44853000,"epsBasic":null,"netIncome":-8945000,"rdExpense":50093000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-25266000},{"sga":24958000,"ebit":-73549000,"ebitda":-66313000,"period":"2025-09-30","revenue":8955000,"epsBasic":-0.19,"netIncome":-57119000,"rdExpense":55028000,"epsDiluted":-0.19,"grossProfit":null,"operatingIncome":-73549000},{"sga":21986000,"ebit":-45893000,"ebitda":-38833000,"period":"2025-06-30","revenue":17084000,"epsBasic":-0.12,"netIncome":-34727000,"rdExpense":39213000,"epsDiluted":-0.12,"grossProfit":null,"operatingIncome":-45893000},{"sga":19068000,"ebit":-58507000,"ebitda":-51902000,"period":"2025-03-31","revenue":4235000,"epsBasic":-0.15,"netIncome":-45621000,"rdExpense":42496000,"epsDiluted":-0.15,"grossProfit":null,"operatingIncome":-58507000},{"sga":19164000,"ebit":-69211000,"ebitda":-55311000,"period":"2024-12-31","revenue":5050000,"epsBasic":null,"netIncome":-34210000,"rdExpense":46076000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-69211000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-0.17,"netIncome":null,"rdExpense":null,"epsDiluted":-0.17,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":4.59,"previousClose":4.77,"fiftyTwoWeekHigh":6.51,"fiftyTwoWeekLow":1.94,"fiftyTwoWeekRange":"1.94 - 6.515","fiftyDayAverage":3.86,"twoHundredDayAverage":4.14,"beta":0,"enterpriseValue":1086217600,"forwardPE":-6.4,"priceToBook":1.43,"priceToSales":17.72,"enterpriseToRevenue":13.71,"enterpriseToEbitda":-5.77,"pegRatio":0,"ebitda":-188284000,"ebitdaMargin":-237.7,"freeCashflow":-105397248,"operatingCashflow":-153264000,"totalDebt":134308992,"debtToEquity":14.3,"currentRatio":14.05,"returnOnAssets":-10,"returnOnEquity":-14.7,"analystRating":"1.3 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":7,"targetMeanPrice":9.71,"targetHighPrice":12,"targetLowPrice":7,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":22.6,"institutionHeldPercent":41.6,"sharesOutstanding":305375393,"floatShares":205322199,"sharesShort":44457643,"shortRatio":8.75,"shortPercentOfFloat":14.6,"epsTrailing":-0.48,"epsForward":-0.72,"revenuePerShare":0.26,"bookValue":3.22,"officers":[{"age":50,"name":"Dr. Carl L.G. Hansen Ph.D.","title":"CEO, President & Chairperson"},{"age":51,"name":"Mr. Andrew  Booth M.B.A.","title":"Chief Financial Officer"},{"age":40,"name":"Dr. Veronique  Lecault Ph.D.","title":"CTO & Director"},{"age":55,"name":"Mr. Tryn T. Stimart Esq., J.D., M.Sc.","title":"Chief Legal Officer, Chief Compliance Officer, Corporate Secretary & Privacy Officer"},{"age":null,"name":"Mr. Andrew  Knowles M.Sc.","title":"Vice President of Operations"},{"age":null,"name":"Mr. Martin  Hogan M.Sc.","title":"Senior Director of Strategic Finance & IR"},{"age":null,"name":"Ms. Tiffany  Chiu B.Sc., Ph.D.","title":"Vice President of Communications"},{"age":null,"name":"Caitlin  Webster CIPD, M.Sc.","title":"Director of Talent Development"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.abcellera.com","phone":"604 559 9005"}}